jpd_2021_11-2_jpd-11-2-jpd202463_jpd-11-jpd202463.pdf (142.06 kB)
COVID-19 and Parkinson's disease: what do we know so far?
Version 2 2023-06-12, 09:51
Version 1 2023-06-09, 23:51
journal contribution
posted on 2023-06-12, 09:51 authored by Carlo Alberto Artusi, Albertoa Romagnolo, Claudia Ledda, Maurizio Zibetti, Mario Giorgio Rizzone, Elisa Montanaro, Marco Bozzali, Leonardo LopianoBackground: Many studies on Parkinson’s disease (PD) patients affected by Coronavirus-disease-2019 (COVID-19) were recently published. However, the small sample size of infected patients enrolled in most studies did not allow to draw robust conclusions on the COVID-19 impact in PD. Objective: We aimed to assess whether the prevalence and outcome of COVID-19 in PD patients are different from those observed in the general population. Methods: We conducted a systematic review of studies reporting data on PD patients with a diagnosis of COVID-19 (PD-COVID+). We extracted prevalence, clinical-demographic data, outcome, and mortality. We also analyzed risk or protective factors based on comparisons between PD-COVID+ and control populations with PD without COVID-19 or without PD with COVID-19. Results: We included 16 studies reporting on a total of 11,325 PD patients, 1,061 with a confirmed diagnosis of COVID-19. The median infection prevalence ranged from 0.6% to 8.5%. PD-COVID+ patients had a median age of 74 and a disease duration of 9.4 years. Pooling all PD-COVID+ patients from included studies, 28.6% required hospitalization, 37.1% required levodopa dose increasing, and 18.9% died. The case fatality was higher in PD-COVID+ patients than the general population, with longer PD duration as a possible risk factor for worse outcome. Amantadine and vitamin D were proposed as potential protective factors. Conclusion: Available studies indicate a higher case fatality in PD patients affected by COVID-19 than the general population. Conversely, current literature does not definitively clarify whether PD patients are more susceptible to get infected. The potential protective role of vitamin D and amantadine is intriguing but deserves further investigation.
History
Publication status
- Published
File Version
- Published version
Journal
Journal of Parkinson's DiseaseISSN
1877-7171Publisher
IOS PressExternal DOI
Issue
2Volume
11Page range
445-454Event location
NetherlandsDepartment affiliated with
- BSMS Neuroscience Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2021-05-13First Open Access (FOA) Date
2021-05-13First Compliant Deposit (FCD) Date
2021-05-12Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC